London-based CRO hVIVO has landed a £16.8 million ($21 million) contract from an unnamed drugmaker to conduct a phase 2 trial of its respiratory syncytial virus (RSV) antiviral drug candidate. The company, which

Stock market listed pharmaceutical services firm Hvivo has signed a £16.8m (€19.5m) contract with an existing pharmaceutical client. The contract will see Hvivo test the pharmaceutical company’s respiratory syncytial virus

Up next in our exclusive series of Congress Conversations from the Barcelona event we are delighted to share an interview with Dr Andrew Catchpole, hVIVO. He joined us at the Congress

Dr Andrew Catchpole, Chief Scientific Officer at hVIVO plc, said: What do we know from the information available? “There are only few very details that have emerged so far but

‘Don’t panic but stay alert’. That is the advice from a top London scientist after the first confirmed human case of a new strain of swine flu in the UK. The virus

hVIVO is the only global CRO focused on the delivery of human challenge trials, with its heritage dating back to the 1940s Common Cold Unit, and is spearheading a long

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

hVIVO will be attending the Jefferies Healthcare Conference: Start Date: 14 Nov 2023 End date: 16 Nov 2023 Location: London, UK hVIVO plc (formerly Open Orphan plc) is a rapidly growing

Venn Life Sciences was requested to perform the non-compartmental pharmacokinetic analysis (NCA) for an oncology trial for a bispecific antibody. For this trial, strict timelines were set to meet the

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge